Head-To-Head Review: Cencora (NYSE:COR) and Progyny (NASDAQ:PGNY)

Cencora (NYSE:COR) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.

Volatility and Risk

Cencora has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Progyny has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Cencora and Progyny, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cencora	0	4	8	1	2.77
Progyny	0	4	6	2	2.83

Cencora presently has a consensus price target of $379.50, indicating a potential upside of 11.44%. Progyny has a consensus price target of $27.50, indicating a potential upside of 2.61%. Given Cencora’s higher possible upside, analysts clearly believe Cencora is more favorable than Progyny.

Profitability

This table compares Cencora and Progyny’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cencora	0.48%	227.15%	4.30%
Progyny	4.46%	10.71%	7.27%

Insider & Institutional Ownership

97.5% of Cencora shares are held by institutional investors. Comparatively, 94.9% of Progyny shares are held by institutional investors. 10.8% of Cencora shares are held by insiders. Comparatively, 9.4% of Progyny shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Cencora and Progyny”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cencora	$321.33 billion	0.21	$1.55 billion	$7.95	42.83
Progyny	$1.17 billion	1.98	$54.34 million	$0.63	42.54

Cencora has higher revenue and earnings than Progyny. Progyny is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.

Summary

Cencora beats Progyny on 9 of the 15 factors compared between the two stocks.

About Cencora

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.